The Research of Standard Diagnosis and Treatment for HSPN in Children

• Status: Recruiting
• Trial end date: 2020-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is performed to evaluate the efficacy and safety of various measures in the treatment of HSPN in children.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanjing Children's Hospital
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Cyclophosphamide; Enzyme Inhibitors; Leflunomide; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Mycophenolate mofetil; Mycophenolic Acid; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Prednisone

Criteria

Inclusion Criteria:

• Renal biopsy proved HSPN Proteinuria ≥ 50 mg/kg/d

Exclusion Criteria:

• The children with congenital diseases Proteinuria < 50 mg/kg/d